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Abstract
Purpose This study explores the current QoL of opiate-
dependent individuals who started outpatient methadone
treatment at least 5 years ago and assesses the inﬂuence of
demographic, psychosocial, drug and health-related vari-
ables on individuals’ QoL.
Methods Participants (n = 159) were interviewed about
their current QoL, psychological distress and severity of
drug-related problems, using the Lancashire Quality of Life
Proﬁle, the Brief Symptom Inventory and the Addiction
Severity Index. Potential determinants of QoL were
assessed in a multiple linear regression analysis.
Results Five years after the start of methadone treatment,
opiate-dependent individuals report low QoL scores on
various domains. No association was found between drug-
related variables and QoL, but a signiﬁcant negative impact
of psychological distress was identiﬁed. Severity of psy-
chological distress, taking medication for psychological
problems and the inability to change one’s living situation
were associated with lower QoL. Having at least one good
friend and a structured daily activity had a signiﬁcant,
positive impact on QoL.
Conclusions Opiate-dependentindividuals’QoLismainly
determined by their psychological well-being and a number
of psychosocial variables. These ﬁndings highlight the
importanceofaholisticapproachtotreatmentandsupportin
methadone maintenance treatment, which goes beyond
ﬁxing the negative physical consequences of opiate
dependence.
Keywords Quality of life  Opiate dependence 
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Introduction
Estimations of the prevalence of opiate use in the European
Union range from 1 to 6 per thousand inhabitants [1].
Although this number is considerably lower when com-
pared with the prevalence of cocaine, cannabis and other
illicit drug use, dependence rates are much higher among
opiate users [2]. Opiates, heroin in particular, remain the
primary drug for which individuals seek treatment and the
vast majority of drug-related infectious diseases and mor-
tality is associated with opiate use [1]. Methadone substi-
tution treatment is the standard, evidence-based treatment
for opiate dependence in most countries [3], but recently
buprenorphine has been introduced as an alternative sub-
stitute drug to reduce heroin use and related health and
social problems.
Given the chronic, relapsing nature of drug problems
and the various life domains they affect [4, 5], the attention
for quality of life (QoL) in the ﬁeld of drug abuse research
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DOI 10.1007/s11136-010-9732-3has grown rapidly [6]. The majority of these studies have
assessed drug users’ health-related quality of life (HRQoL)
[7–9], especially among opiate-dependent individuals in
treatment [6]. Evidence is available that the HRQoL of
opiate-dependent individuals is low in comparison with the
general population and individuals suffering from other
chronic diseases and most comparable with that of indi-
viduals with psychiatric problems [10, 11]. In general,
opiate-dependent individuals report poor mental health
scores, while their scores for physical functioning are
usually considerably higher [12]. HRQoL is a concept
frequently misused as a synonym for QoL [13, 14]. It
primarily focuses on the effects of a disease on individuals’
daily functioning [15], with special attention for their
physical and mental health [11, 16].
The comprehensive concept of QoL has a more positive
connotation and focuses on persons’ overall well-being and
satisfaction with life [17]. Such a holistic approach to QoL
with attention for drug users’ own experiences and
expectations is often lacking in drug abuse research. Up till
now, the focus in most studies is exclusively on the absence
of pathology and individuals’ functional status (HRQoL).
However, it is necessary to make a distinction between
HRQoL and QoL, since individuals’ health status may have
an impact on QoL, but does not represent it [18]. Health is
included as an important domain in most QoL deﬁnitions
[13], but when individuals are asked to deﬁne important
domains of QoL health is seldom mentioned as a primary
domain [19, 20]. A qualitative study concerning drug users’
perspectives on the concept QoL demonstrated that social
inclusion and self-determination are regarded as central
components of QoL [20]. On the other hand, some quan-
titative studies have identiﬁed health-related issues as
determinants of QoL [21–23], illustrating the possible
inﬂuence of health status on the concept QoL.
A limited number of studies have reported lower QoL
scores for opiate-dependent individuals when compared
with the general population or a non-clinical control group
[21, 24, 25]. Only recently QoL has become an outcome
measure in research on the effectiveness of (various forms
of) substitution treatment [3, 26–28]. In general, opiate-
dependent individuals report low QoL and HRQoL scores
at admission to substitution treatment [12]. Participation in
substitution treatment brings about positive effects on
individuals’ HRQoL and QoL, especially during the ﬁrst
months of treatment [9, 28–33]. However, a stabilization of
these improvements or even less favorable outcomes can
be noticed from a long-term perspective [30, 34].
A better understanding of determinants that are associ-
ated with high QoL scores may advice treatment services
and policymakers how they can improve individuals’ QoL
[35]. Studies that provide information on predictors of QoL
among opiate-dependent persons are limited and have
mainly focused on HRQoL. Moreover, these studies have
not resulted in unequivocal ﬁndings. An inverse relation-
ship between age and HRQoL has been shown in various
studies [36–38], while inconsistent ﬁndings have been
reported regarding the role of gender [10, 30, 36, 38, 39].
The impact of severity of dependence on HRQoL remains
unclear [10, 36, 40–42], but the negative impact of
excessive alcohol use on HRQoL has been demonstrated in
several studies [8, 41, 43]. Emotional and psychiatric
problems (e.g., depression, personality disorders) appear to
have a detrimental impact on individuals’ HRQoL [36, 44,
45]. Social support may have a positive inﬂuence on
HRQoL [7], but conﬂicts with family and partner have
been associated with lower HRQoL scores [41]. As dem-
onstrated by Millson and colleagues [36], who identiﬁed
more than a dozen different determinants of the mental and
physical composite scores of the SF-36, opiate-dependent
individuals’ HRQOL is affected by multiple factors.
Besides the limited number of studies on determinants
of QoL, few authors have controlled for the inﬂuence of
potential covariates in a multivariate design. Consequently,
results are often limited to bivariate analyses of correlates
of QoL [25, 46, 47]. Despite the speciﬁc treatment needs of
opiate users, only one study by Bizzarri and colleagues [21]
examined the independent impact of dual diagnosis, gen-
der, age and current substance use on QoL of opiate-
dependent individuals, using the WHOQOL-BREF. This
study demonstrated a signiﬁcant impact of dual diagnosis
on all four QoL domains, a negative association of older
age and female gender with some domains, while current
substance use had no signiﬁcant impact on QoL. Also,
Conroy and colleagues [48] found no association between
QoL and drug-using practices (e.g., drug use, sharing of
needle equipment) among injecting drug users, but a range
of psychosocial factors (e.g., family support, having
friends) inﬂuenced their current QoL. According to another
study, the overall QoL of substance users in treatment was
negatively associated with older age, speciﬁc medical
conditions (i.e., arthritis, ulcers), severity of drug use,
being treated in a detoxiﬁcation unit and recent hospital-
ization for mental health problems [22]. Finally, improve-
ment of psychiatric symptoms was demonstrated to be the
best predictor of increased QoL among severely mentally
ill substance abusers [23].
Given the dearth of research on predictors of QoL
among opiate-dependent individuals and given the assump-
tion that substitution treatment contributes to the stabil-
ization of opiate users’ living situation, the aim of this
article is to study the current QoL of persons who started
outpatient methadone treatment at least 5 years ago. Fur-
thermore, the inﬂuence of recent heroin use and psycho-
logical distress on current QoL is assessed, as well as the
question which demographic, psychosocial, drug and
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better QoL.
Methods
Subjects and data collection
This study was set up as a cross-sectional study of the
current QoL of a cohort of opiate-dependent individuals
who started outpatient methadone treatment between 1997
and 2002 in the region of Ghent (Belgium). This time
frame was chosen, since the ﬁrst medical-social care center
for outpatient methadone treatment (MSOC) was opened in
1997 and since we intended to monitor the current situation
of opiate-dependent persons who started methadone treat-
ment at least 5 years ago. No central methadone register
was available from the beginning, but it has been estimated
that during this period (1997–2002) between 1,000 and
1,500 persons have been involved in methadone treatment
in this region [49, 50].
Inclusion criteria for the study were being over 18 years,
a diagnosis of opiate dependence at the start of methadone
treatment and having started this treatment in the region of
Ghent between January 1997 and December 2002. Partic-
ipants were recruited by the use of various media (e.g.,
ﬂyers, advertisements in newspapers, interviews on local
television and radio), through snowball sampling and by
staff members of methadone programs for the group still in
treatment. In addition, the regional network of drug treat-
ment agencies informed eligible drug users about the study.
Individuals were excluded from the study if the interview
could not be administered in Dutch (n = 2), if methadone
treatment was started after 2002 (n = 10) or outside the
region of Ghent (n = 13) or when they just received
methadone as part of residential detoxiﬁcation (n = 5).
In total, 159 subjects participated in this non-random-
ized study. Forty-one participants (25.8%) were no longer
in methadone treatment by the time of the interview, while
almost three-quarters of the sample (74.2%) was currently
still on methadone. The mean duration of methadone
treatment was 7.6 years (SD = 4.4). A high proportion of
the sample (86.5%) followed at least two methadone
treatment episodes, which is not surprising given the high
drop-out rates in substitution treatment [51].
Interviews took place between March 2008 and August
2009 and lasted between 45 and 120 min. Individuals
received 20€ for participation in the study. A written
informed consent was obtained from all participants before
the start of the study. Participation was entirely voluntary
and conﬁdentiality was assured. Data were collected during
face-to-face interviews in a setting of the participants’
choice (e.g., at the methadone clinic, in the person’s house,
in a public place, in a residential treatment center). Inter-
views focused on respondents’ current QoL and on lifetime
and current severity of substance use and related problems.
The study was approved by the ethical committee of the
Faculty of Psychology and Educational Sciences of the
Ghent University, in accordance with internationally
accepted criteria for research (2006/51).
Instruments
The Lancashire quality of life proﬁle
In order to measure individuals’ current QoL, we made use
of the modiﬁed Dutch version of the Lancashire Quality of
Life Proﬁle, an instrument commonly used in mental health
research [52, 53]. The LQOLP has been used in a number
of studies among opiate-dependent individuals to measure
effects of substitution treatment on QoL [26, 33, 34, 46,
54–56]. The LQOLP measures individuals’ satisfaction
with various QoL domains and their global well-being. The
Dutch version of the LQOLP consists of ten subscales:
‘‘health’’, ‘‘leisure and social participation’’, ‘‘living situa-
tion’’, ‘‘family relations’’, ‘‘ﬁnances’’, ‘‘safety’’, ‘‘positive
self-esteem’’, ‘‘negative self-esteem’’ (measured by a
modiﬁed version of the Self-Esteem Scale; [57]), ‘‘frame-
work’’ and ‘‘fulﬁllment’’. Perceived QoL or individuals’
subjective ratings are assessed on a 7-point Likert scale
(from ‘‘1. Life cannot be worse’’ to ‘‘7. Life cannot be
better’’) for all domains, except the domains ‘‘positive self-
esteem’’, ‘‘negative self-esteem’’, ‘‘framework’’ and ‘‘ful-
ﬁllment’’. The latter are measured on a 3-point Likert scale
but were afterward recoded on a 7-point Likert scale. Low
QoL has been deﬁned as ‘‘a score below 4’’ [58]. Besides
these speciﬁc QoL domains, global well-being is assessed
by means of Cantril’s ladder [59], a happiness scale [60]
and an average life satisfaction score (‘‘how satisﬁed are
you with your life as a whole?’’). The LQOLP also contains
objective items on various life domains (e.g., occupation,
housing situation, psychological problems) [61]. Internal
consistency, reliability and validity of the LQOLP have
been demonstrated to be satisfactory [52, 53, 62]. For the
purpose of this study, we make use of the 10 domain
scores, the average life satisfaction score (to measure
global well-being) and a total QoL score, a sum score
based on the ten speciﬁc QoL domain scores [63].
The EuropASI
In order to measure the severity of substance use and
related problems, we used the EuropASI, an adapted and
validated version of the Addiction Severity Index (ASI) for
the European context [64, 65]. The EuropASI is a semi-
structured clinical interview, including an assessment on
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123seven areas of functioning: medical status, employment/
support, alcohol use, drug use, legal problems, family/
social relationships and psychological problems [66]. An
ASI composite score is calculated for each domain (range
0–1), with higher scores indicating higher problem severity
[67]. In this study, only the domains ‘‘medical status’’,
‘‘alcohol’’, ‘‘drugs’’ and ‘‘legal status’’ were assessed, since
‘‘family’’, ‘‘employment’’ and ‘‘psychological problems’’
were extensively explored as part of the objective items of
the LQOLP. It is a valid approach to assess ASI domains
separately.
Brief symptom inventory
The Dutch version of the Brief Symptom Inventory (BSI),
a short version of the widely applied SCL-90, was used to
measure psychological distress. This is a validated, multi-
dimensional self-report questionnaire, consisting of 53
items [68]. Psychometric properties of the BSI have been
demonstrated to be sufﬁcient [68, 69]. The instrument
measures recent psychological complaints (past 7 days)
on 9 subscales: ‘‘somatization’’, ‘‘obsessive–compulsive’’,
‘‘interpersonal sensitivity’’, ‘‘depression’’, ‘‘anxiety’’,
‘‘hostility’’, ‘‘phobic anxiety’’, ‘‘paranoid ideation’’ and
‘‘psychoticism’’. Symptoms are rated on a 5-point Likert
scale ranging from ‘‘0. Not at all’’ to ‘‘4. Extremely’’, with
higher scores indicating severe complaints [68]. A Global
Severity Index (GSI), an average rating of all 53 items
(range 0–4), is calculated as an overall score of psycho-
logical functioning. Clinical cut-off scores for psycholog-
ical distress are available for all 9 subscales and the GSI.
The cut-off score of the GSI (0.70) is used as a general
measure of psychopathology [68, 69]. Besides the GSI, the
positive symptom distress index (PSDI) measures the
intensity of symptoms, while the positive symptom total
(PST) represents the number of items indicating psycho-
logical distress.
Statistical analyses
The characteristics of the sample were assessed using
descriptive statistics. Domain-based QoL scores and a
global well-being score were calculated. A proﬁle was
determined, including the number of respondents with low
QoL on each domain and low global well-being. Inde-
pendent samples t-tests were used to compare domain
scores and global well-being between subjects who
recently used heroin and those who did not do so. In
addition, respondents who scored higher than the clinical
cut-off score for overall psychopathology were compared
with those with a GSI below 0.70. A Bonferroni correction
was applied to address the problem of multiple compari-
sons and to protect against type 1 errors in the bivariate
analyses. To investigate the independent contribution of
individual predictors to QoL, a multiple linear regression
model was built using a stepwise search procedure
including forward selection as well as backward elimina-
tion. The dependent variable (total QoL) was compiled as a
sum score of the ten speciﬁc domain-based QoL scores.
The 28 predictors initially included in the stepwise search
were selected based on associations found in previous
research and based on existing theories and conceptual-
izations of QoL [70–72]. The following predictors were
entered: gender, age, educational level, employment, hav-
ing debts, inability to change living situation in the past
year, having an intimate relationship, having at least one
good friend, having a structured form of daily activities,
having been convicted of a crime in the past year, inability
to have more contact with own family in the past year, age
at ﬁrst heroin use, age at ﬁrst methadone use, years of
regular heroin use, years of regular methadone use,
injecting behavior, number of days in outpatient drug or
alcohol treatment during the last 30 days, currently in
methadone treatment, number of methadone treatments,
taking medication for psychological problems, ever been
hospitalized for psychological problems, been a victim of
violence in the past year, having chronic medical com-
plaints, ASI drug composite score, ASI alcohol composite
score, ASI composite score for medical status, ASI com-
posite score for legal status and the Global Severity Index
of the BSI. We acknowledge that the sample size
(n = 159) is relatively small to test this large number of
predictors. Therefore, we used resampling techniques
(bootstrapping), which conﬁrmed the validity of the ﬁnal
model. The ﬁnal model is presented in the ‘‘Results’’ sec-
tion. All model assumptions were satisﬁed, and no signif-
icant multicollinearity was present between the predictors
in the ﬁnal model. All statistics were done using SPSS
15.0. The statistical signiﬁcance level was set at a = 0.05.
Results
Study sample characteristics
Study participants were predominantly male (74.8%), with
an average age of 36.6 years (SD = 7.5) (see Table 1). Of
them, 56.6% did not complete any form of secondary
education. About one-quarter of the participants (26.4%)
currently had a paid job. The largest group of subjects had
never been married (69.8%) and lived alone (40.3%). The
mean age of onset of regular heroin use was 21.4 years
(SD = 5.6), and they had been consuming heroin regularly
for, on average, 10.8 years (SD = 6.7). About half of the
participants (49.7%) reported recent heroin use. The mean
age of onset of regular methadone use was 26.0 years
142 Qual Life Res (2011) 20:139–150
123(SD = 6.4). On average, they had been taking methadone
during 7.6 years (SD = 4.4). Of the sample, 54.1% scored
above the clinical cut-off score for overall psychopathol-
ogy, while 87.9% of the sample scored above the clinical
cut-off score for psychological distress for at least one
subscale of the BSI. ‘‘Paranoid ideation’’ (65.6%) was the
most frequently reported psychological complaint within
the clinical range, followed by ‘‘somatization’’ (56.7%) and
‘‘psychoticism’’ (55.4%).
Current quality of life
Individuals who had started outpatient methadone treat-
ment between 5 and 10 years ago appeared most satisﬁed
at the moment with the domains ‘‘framework’’, ‘‘positive
self-esteem’’ and ‘‘safety’’ (see Table 2). The domain
‘‘framework’’, which relates to having meaningful per-
spectives in life, had the highest average satisfaction score.
Respondents were least satisﬁed with their ‘‘ﬁnances’’ and
‘‘family relations’’.
While the mean scores provide an overall picture for the
total sample, Fig. 1 shows the number of individuals
reporting a low QoL (score\4) on the various domains.
The results are divergent between the domains, with in
particular a large number of subjects with a low QoL score
for ‘‘ﬁnances’’ (68.6%) and ‘‘family relations’’ (44.9%).
Also, more than 30% of the participants had a low
QoL concerning ‘‘living situation’’ (34.0%), ‘‘negative
Table 1 Sociodemographic and drug use-related characteristics of
opiate-dependent individuals who started methadone treatment
between 1997 and 2002 (N = 159)
Characteristics Sample
Age [M (SD)] 36.6 (7.5)
Male (%) 74.8
Marital status (%)
Unmarried 69.8
Married 7.5
Divorced/widowed 22.6
Intimate relationship (%) 45.3
One or more children (%) 50.9
Paid job (%) 26.4
Age at ﬁrst use [M (SD)]
Heroin 21.4 (5.6)
Methadone 26.0 (6.4)
Years of regular use [M (SD)]
Heroin 10.8 (6.7)
Methadone 7.6 (4.4)
Injecting behavior (%)
Ever 81.8
In the last 30 days 27.8
Substance use in the last 30 days (%)
Alcohol 61.0
Cannabis 59.2
Benzodiazepines 57.2
Heroin 49.7
Cocaine 31.4
Antidepressants 27.2
Average duration of methadone treatment episode (%)
\3 months 11.8
3–6 months 6.5
[6 months 10.5
[12 months 71.2
Average dose of methadone (%)
1–39 mg 39.5
40–59 mg 24.3
60–109 mg 28.9
[109 mg 7.2
Consulted a doctor for psychological problems during
the last year (%)
45.3
Taken medication for psychological problems during
the last year (%)
58.5
Psychological complaints [M (SD)]
Somatization .89 (.81)
Obsessive–compulsive 1.14 (.88)
Interpersonal sensitivity 1.11 (1.02)
Depression 1.12 (.97)
Anxiety 1.04 (.90)
Hostility .80 (.82)
Phobic anxiety .58 (.68)
Table 1 continued
Characteristics Sample
Paranoid ideation 1.13 (.85)
Psychoticism .78 (.74)
Overall psychopathology .98 (.70)
Table 2 Mean scores (range 1–7) for the 10 domains and global
well-being of the LQOLP for individuals who started methadone
treatment between 1997 and 2002 (N = 159)
Life domain Mean SD
Framework 6.05 1.0
Positive self-esteem 5.96 1.3
Safety 5.23 1.0
Fulﬁllment 4.69 1.1
Negative self-esteem 4.68 1.5
Health 4.54 .95
Leisure and social participation 4.41 .95
Living situation 4.34 1.4
Family relations 3.94 1.7
Finances 3.31 1.4
Global well-being 4.04 1.5
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123self-esteem’’ (32.1%) and ‘‘fulﬁllment’’ (31.4%). Low sat-
isfaction with fulﬁllment means that those subjects do not
feel able to fulﬁll their life goals or have difﬁculties real-
izing their life goals. In comparison with the other domains,
relatively few subjects (24%) reported low QoL concerning
health issues. Overall, 31.4% of the respondents appear to
be dissatisﬁed with their current global well-being.
Impact of current heroin use and psychological distress
on QoL
The sample was split up into two subgroups, based on the
presence or absence of recent heroin use (last 30 days).
Only the domain score for ‘‘ﬁnances’’ was signiﬁ-
cantly lower among recent heroin users (t(157) = 2.998,
P = .003), while current heroin use did not affect other
QoL domains (Table 3).
A comparison of the respondents who scored higher
than the clinical cut-off score for overall psychopathology
(C0.70) with those who did not score within the clinical
range showed a strong negative impact of current psy-
chological distress on QoL. The former group had
signiﬁcantly lower scores on all QoL domains and for
global well-being (Table 4).
Determinants of QoL
In order to determine which factors inﬂuenced total QoL, a
multiple linear regression analysis was conducted. The
ﬁnal model obtained through stepwise regression is pre-
sented in Table 5. It contains ﬁve predictor variables,
jointly explaining 60% of the variance of the total QoL
score. Higher scores for psychological distress, inability to
change one’s living situation and taking medication for
psychological complaints were signiﬁcantly associated
with lower QoL. On the other hand, having at least one
good friend and having a structured daily activity signiﬁ-
cantly predicted a higher QoL score. The strongest negative
predictor of total QoL was the total score for psychological
distress, while having at least one good friend was the
predictor with the strongest positive impact on total QoL.
Discussion
This study revealed low QoL scores on various domains
among opiate-dependent individuals 5–10 years after they
had started outpatient methadone treatment. Although no
general population norms are available with which these
results can be compared, a signiﬁcantly higher proportion
of the study sample reported low QoL on six of the ten
LQOLP domains in comparison with hospitalized male
psychiatric patients [58]. This ﬁnding can be partly
explained by the high prevalence of psychological com-
plaints in the study sample. Various studies have demon-
strated high psychiatric co-morbidity in opiate-dependent
individuals (in methadone treatment) [45, 73–75]. Previ-
ous studies on QoL of opiate-dependent individuals
have reported lower QoL scores among persons with
Table 3 Comparison of the
mean scores for the 10 domains
and global well-being of the
LQOLP between individuals
who recently used heroin and
those who did not (N = 159)
* Signiﬁcant at the Bonferroni-
corrected P\0.005 level
Life domain No heroin use
(n = 80), [M (SD)]
Heroin use
(n = 79), [M (SD)]
t(df) P
Framework 6.2 (1.0) 5.9 (1.0) 1.67(157) .096
Positive self-esteem 6.0 (1.3) 5.9 (1.3) .32(157) .749
Safety 5.3 (1.0) 5.2 (1.1) .52(157) .605
Fulﬁllment 4.8 (1.1) 4.5 (1.1) 1.72(157) .088
Negative self-esteem 4.8 (1.5) 4.6 (1.5) 1.00(157) .317
Health 4.6 (0.9) 4.5 (1.0) .15(157) .882
Leisure and social participation 4.5 (0.9) 4.3 (1.0) 1.65(157) .100
Living situation 4.4 (1.4) 4.3 (1.5) .16(157) .874
Family relations 4.1 (1.6) 3.7 (1.8) 1.38(157) .168
Finances* 3.6 (1.4) 3.0 (1.2) 3.00(157) .003*
Global well-being 4.2 (1.6) 3.8 (1.4) 1.71(157) .089
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Fig. 1 Proportion of respondents reporting low QoL for each speciﬁc
domain and global well-being (N = 159)
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123co-occurring psychiatric problems when compared with
individuals without psychiatric co-morbidity [12]. Similar
ﬁndings can be observed in studies among persons with
severe mental illnesses, in which a negative effect of
substance abuse on QoL has been demonstrated [76, 77]. It
appears that individuals with a so-called dual diagnosis are
more vulnerable for having a poor QoL. Given the high
prevalence of psychological symptoms in opiate-dependent
individuals, it can be questioned whether it would not be
more appropriate to develop integrated mental health and
substance abuse services as the standard of care [78].
Persons who started methadone treatment more than
5 years ago are generally dissatisﬁed with their ‘‘ﬁnances’’.
This has also been observed in other studies that have used
the LQOLP to assess the effectiveness of opiate substitu-
tion treatment [33, 34, 54–56]. The dissatisfaction with
their ﬁnancial situation may not be surprising, given the
high cost of supporting a drug consumption habit [79] and
drug users’ substantial debts. Individuals’ poor education
and unemployment may further affect their social and
economic situation [45, 80, 81]. Yet, the domain ‘‘ﬁnan-
ces’’ also appears to be the domain with the lowest satis-
faction among the general population [82].
The high mean score on the domain ‘‘framework’’
shows that opiate-dependent individuals have a sense of
purpose with their life and future plans that give them
satisfaction. Life meaning is important to buffer stress, and
has in its turn a positive inﬂuence on QoL [83]. Studies by
Moomal [84] and Zika and Chamberlain [85] have dem-
onstrated a clear association between life meaning and
psychological well-being. Life meaning is a domain that
needs more attention in QoL measurements, given the high
importance that is attributed to this domain by persons with
drug and mental health problems [20, 53]. The high pro-
portion of subjects who report a low QoL on the domain
‘‘fulﬁllment’’ indicates that many opiate-dependent indi-
viduals think it will be very difﬁcult to actually realize their
desired life goals. Experiences of stigma [86] and dis-
crimination [87] often hinder drug users in their daily
functioning and are associated with poor mental and
physical health [88].
Low scores on one QoL domain do not necessarily
imply low scores on another domain, illustrating the
necessity to assess QoL from a multidimensional per-
spective. The relatively high scores on the domain ‘‘health’’
demonstrate the appropriateness of methadone programs
Table 4 Comparison of the
mean scores for the 10 domains
and global well-being of the
LQOLP between persons with
an overall psychopathology of
C0.70 score and persons with a
lower score (N = 157)
* Signiﬁcant at the Bonferroni-
corrected P\0.005 level
Life domain No psychopathology
(n = 72), [M (SD)]
Psychopathology
(n = 85), [M (SD)]
t(df) P
Framework 6.3 (0.8) 5.8 (1.1) 3.09(152.96) .002*
Positive self-esteem 6.6 (0.8) 5.5 (1.4) 6.17(133.66) .000*
Safety 5.5 (0.9) 5.0 (1.1) 3.16(153.06) .002*
Fulﬁllment 5.2 (1.0) 4.2 (1.0) 5.70(155) .000*
Negative self-esteem 5.5 (1.4) 4.0 (1.2) 7.08(155) .000*
Health 5.0 (0.8) 4.2 (0.9) 6.07(155) .000*
Leisure and social participation 4.7 (0.7) 4.2 (1.0) 3.98(147.86) .000*
Living situation 4.8 (1.2) 4.0 (1.5) 3.60(154.47) .000*
Family relations 4.4 (1.6) 3.6 (1.7) 3.02(155) .003*
Finances* 3.7 (1.3) 3.0 (1.3) 3.17(155) .002*
Global well-being 4.5 (1.4) 3.7 (1.5) 3.36(155) .001*
Table 5 Final model of the linear multivariate regression analysis including signiﬁcant predictors of total QoL
Remaining predictors B SE Beta tP
(Constant) 5.420 .138 39.36 .000
Global Severity Index/psychological distress -.573 .060 -.539 -9.50 .000
Inability to change living situation -.441 .093 -.252 -4.75 .000
Medication for psychological complaints -.300 .083 -.197 -3.62 .000
Good friend .309 .089 .184 3.48 .001
Structured daily activities .228 .087 .147 2.62 .010
R
2 = .616
Adjusted R
2 = .602
P\.05
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123for reducing health problems, but—in combination with the
previous observation—also stress the need for looking
beyond health-related aspects. Generally, measuring QoL
should be given a more prominent role in the assessment
and monitoring of drug problems, starting from individu-
als’ needs and expectations in order to postulate and adjust
treatment goals [89].
To our knowledge, this is the ﬁrst study applying a
multivariate design to assess the independent impact of
various demographic, psychosocial, drug- and health-rela-
ted determinants on QoL among opiate-dependent indi-
viduals who started methadone treatment at least 5 years
ago. This study conﬁrms the ﬁndings of Conroy [48] and
Bizzarri [21], who found no association between drug-
related variables and the QoL of injecting drug users.
Neither the ASI composite scores for drugs and alcohol,
nor other drug-related variables, nor current treatment
status were signiﬁcant determinants of QoL. Also, in a
validation study of the IDUQOL [90], very low and non-
signiﬁcant correlations were observed between several
drug-related variables and overall QoL. Bivariate com-
parisons of study subjects who recently used heroin and
persons who did not do so, only showed a signiﬁcantly
lower mean QoL score for the domain ‘‘ﬁnances’’ among
current heroin users. These ﬁndings illustrate the limited
inﬂuence of severity of drug use problems on current QoL
and highlight the need for treatment goals other than
stopping or reducing drug use. Being abstinent from drugs
or reduced drug problem severity is not necessarily
accompanied by improvements in QoL, since giving up the
positive aspects associated with drug use (e.g., prestige/
status in the drug scene) and coping with various stressors
(e.g., loneliness, boredom, discrimination) may have a
negative impact on individuals’ QoL [20].
Psychological distress appears to have the strongest
negative impact on current QoL. As much as 25% of the
variance of total QoL was independently explained by the
severity of psychological distress. Also, taking medication
for psychological complaints has a strong negative impact
on QoL. Both determinants demonstrate the strong nega-
tive impact of psychological problems on the current QoL
of opiate-dependent individuals. Consequently, early
identiﬁcation of psychological problems based on system-
atic assessment procedures and attention for the issue of
co-morbidity during the treatment process is a prerequisite
in methadone treatment.
Contextual factors, such as having a good friend and a
structured daily activity, had a signiﬁcant positive inﬂu-
ence on the total QoL of opiate-dependent individuals. The
protective role of social support on drug consumption [91,
92] and retention in treatment [93] has been shown in
various studies. The observation that social networks have
a positive impact on opiate-dependent persons’ QoL
stresses the need for establishing individuals’ (non-pro-
fessional) social networks during and after methadone
treatment in order to enhance their social inclusion. This is
further illustrated by the positive impact of having daily
activities on total QoL: not necessarily employment, but
having a meaningful plan for the day showed a positive
association with total QoL. Meaningful day activities and
social support are both generic determinants of QoL and
have also been identiﬁed as protective factors for QoL
among the general population and speciﬁc subpopulations
(e.g., persons with depressive disorders, disabilities)
[94–98]. The inability to change one’s living situation
during the past year further had a signiﬁcant negative
impact on persons’ total QoL. The importance of stable
housing for individuals’ QoL has been recognized in
various studies on QoL of dually diagnosed individuals
[48, 99]. These independent correlates of QoL illustrate
the need to assist opiate users in methadone treatment with
housing and occupational issues. The inﬂuence of elements
other than health-related factors (e.g., having an occupa-
tion, a good friend) on QoL cannot be underestimated. Due
to a unilateral focus on health, caregivers may only have a
partial picture of clients’ QoL and the various factors
inﬂuencing it [19]. Furthermore, improving one’s QoL [17,
100] and tackling non-health-related problems (e.g., family
relations, legal status, employment status) have been
identiﬁed as the main reasons for going into treatment
[38].
Ultimately, this study has revealed that opiate-depen-
dent individuals still need support on various life domains
5–10 years after starting methadone treatment and that a
satisfactory QoL is in particular mediated by psychological
well-being and some psychosocial variables. Consequently,
a more holistic approach to methadone maintenance—and
drug treatment in general—is recommended, which goes
beyond pharmaceutical maintenance and medical care to
include speciﬁc attention for psychological complaints and
support in housing, occupational and social inclusion issues
[36, 45, 101].
Limitations of the study
Some limitations of this study should be taken into
account. First, the sample size (n = 159) was relatively
small. Findings may therefore not be generalized to other
groups of opiate users. Second, respondents were not
selected randomly, nor did we apply a controlled design. It
is unclear if the sample was fully representative for the
group of opiate-dependent individuals starting methadone
treatment 5–10 years ago (n = 1,500), but the age and
gender distribution of the sample was identical to that of
persons in outpatient methadone treatment in the region of
Ghent between 1997 and 2002 [50]. The representativeness
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123of the sample was enhanced by applying various strategies
to recruit study participants (e.g., ﬂyers, media campaign,
contacts with drug, health and social services). It would
further be interesting to focus in future research on the QoL
of other groups of drug users (e.g., cocaine users, opiate
users out of treatment) [102] and compare these ﬁndings
with those reported here. Third, given the cross-sectional
design of the study, causality could not be examined. This
study only reports associations, because possible determi-
nants and outcomes were measured at the same time.
Future longitudinal research should address issues of
directionality and linearity. Fourth, psychological distress
was measured by means of a short symptom checklist
(BSI). Consequently, the prevalence of psychiatric disor-
ders was not assessed, as no standardized diagnostic
instrument was used. Still, validation studies have shown
high correlations between BSI subscales and diagnostic
instruments measuring the same constructs [68]. Fifth, 60%
of the variance of total QoL was explained by our ﬁnal
regression model, illustrating that other factors (not inclu-
ded in the model) will have had an impact on total QoL.
Qualitative in-depth interviews could provide more infor-
mation on how drug users perceive QoL and on factors that
affect the QoL of drug-using individuals [20, 103]. Finally,
given the conceptual discrepancy between QoL and
HRQoL, researchers need to make explicit what they are
measuring exactly. Therefore, it would be interesting to
compare both concepts—QoL and HRQoL—in future
research, in order to illustrate the different conceptualiza-
tion of both concepts.
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